IL300373A - Beneficial treatments for disorders mediated by IKAROS or AIOLOS - Google Patents

Beneficial treatments for disorders mediated by IKAROS or AIOLOS

Info

Publication number
IL300373A
IL300373A IL300373A IL30037323A IL300373A IL 300373 A IL300373 A IL 300373A IL 300373 A IL300373 A IL 300373A IL 30037323 A IL30037323 A IL 30037323A IL 300373 A IL300373 A IL 300373A
Authority
IL
Israel
Prior art keywords
compound
certain embodiments
administered
combination
treatment
Prior art date
Application number
IL300373A
Other languages
English (en)
Hebrew (he)
Original Assignee
C4 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C4 Therapeutics Inc filed Critical C4 Therapeutics Inc
Publication of IL300373A publication Critical patent/IL300373A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL300373A 2020-08-07 2021-08-06 Beneficial treatments for disorders mediated by IKAROS or AIOLOS IL300373A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063063011P 2020-08-07 2020-08-07
US202163173160P 2021-04-09 2021-04-09
US202163212463P 2021-06-18 2021-06-18
PCT/US2021/045000 WO2022032132A1 (en) 2020-08-07 2021-08-06 Advantageous therapies for disorders mediated by ikaros or aiolos

Publications (1)

Publication Number Publication Date
IL300373A true IL300373A (en) 2023-04-01

Family

ID=80118544

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300373A IL300373A (en) 2020-08-07 2021-08-06 Beneficial treatments for disorders mediated by IKAROS or AIOLOS

Country Status (12)

Country Link
US (1) US20230190760A1 (cg-RX-API-DMAC7.html)
EP (1) EP4192450A4 (cg-RX-API-DMAC7.html)
JP (2) JP7846086B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230049678A (cg-RX-API-DMAC7.html)
CN (1) CN116194438B (cg-RX-API-DMAC7.html)
AU (1) AU2021322285B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023002225A2 (cg-RX-API-DMAC7.html)
CA (1) CA3173658A1 (cg-RX-API-DMAC7.html)
IL (1) IL300373A (cg-RX-API-DMAC7.html)
MX (1) MX2023001545A (cg-RX-API-DMAC7.html)
TW (1) TWI887465B (cg-RX-API-DMAC7.html)
WO (1) WO2022032132A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
KR102947433B1 (ko) * 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
SMT202600194T1 (it) * 2019-10-21 2026-05-12 Celgene Corp Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica
US11807620B2 (en) 2020-02-21 2023-11-07 Plexium, Inc. Quinazolinone compounds and related compounds
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
CA3194351A1 (en) * 2020-10-14 2022-04-21 Christopher G. Nasveschuk Tricyclic compounds to degrade neosubstrates for medical therapy
JP7863100B2 (ja) * 2020-10-14 2026-05-20 シーフォー セラピューティクス, インコーポレイテッド Ikzf2又はikzf4を分解する三環式リガンド
JP7807110B2 (ja) * 2021-08-27 2026-01-27 ハンチョウ グルビオ ファーマシューティカル カンパニー,リミティド イソインドリノン化合物およびその使用
JP2025505687A (ja) * 2022-02-09 2025-02-28 シーフォー セラピューティクス, インコーポレイテッド Cft7455のモルフィック形態及びその製造方法
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
WO2024193641A1 (zh) * 2023-03-21 2024-09-26 上海超阳药业有限公司 异吲哚啉衍生物和苯并吲哚衍生物及其应用
JP2026524477A (ja) 2023-06-30 2026-07-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Krasの分解のためのヘテロ二官能性化合物
CN122206684A (zh) 2023-06-30 2026-06-12 默克专利有限公司 用于kras蛋白降解的异双功能化合物
CN121620373A (zh) * 2024-07-26 2026-03-06 上海超阳药业有限公司 苯并吲哚衍生物的药物组合物、制备方法及用途
WO2026065268A1 (en) * 2024-09-29 2026-04-02 Biofront Ltd Novel conjugates for protein degradation, compositions comprising the same, and methods of using the same
WO2026139448A1 (en) 2024-12-23 2026-07-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
CN120138159A (zh) * 2025-04-30 2025-06-13 徐州医科大学 Nup35基因作为胶质母细胞瘤诊断、预后及治疗靶点的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012175481A1 (en) * 2011-06-20 2012-12-27 Institut Curie Compositions and methods for treating leukemia
CN111662226B (zh) * 2015-01-28 2022-03-18 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物
EP4717317A3 (en) * 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN111902141A (zh) * 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
US10905684B2 (en) 2018-06-13 2021-02-02 Biotheryx, Inc. Aminoamide compounds
KR102947433B1 (ko) * 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제

Also Published As

Publication number Publication date
CA3173658A1 (en) 2022-02-10
EP4192450A1 (en) 2023-06-14
AU2021322285A1 (en) 2023-04-13
JP2023538520A (ja) 2023-09-08
BR112023002225A2 (pt) 2023-03-07
KR20230049678A (ko) 2023-04-13
US20230190760A1 (en) 2023-06-22
TWI887465B (zh) 2025-06-21
MX2023001545A (es) 2023-05-03
JP2026117027A (ja) 2026-07-14
CN116194438A (zh) 2023-05-30
AU2021322285B2 (en) 2026-08-13
JP7846086B2 (ja) 2026-04-14
WO2022032132A1 (en) 2022-02-10
CN116194438B (zh) 2026-08-07
TW202220981A (zh) 2022-06-01
EP4192450A4 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
US20230190760A1 (en) Advantageous therapies for disorders mediated by ikaros or aiolos
US12486253B2 (en) Therapeutics for the degradation of mutant BRAF
US20230339902A1 (en) Tricyclic ligands for degradation of ikzf2 or ikzf4
KR20250065935A (ko) 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법
EP4735438A2 (en) Heterobifunctional compounds for the degradation of kras
US20240391912A1 (en) Morphic forms of cft7455 and methods of manufacture thereof
JP2024521791A (ja) 脳又はcnsへの癌転移を治療するためのegfrデグレーダー
JP2025540907A (ja) Ret-lddタンパク質分解誘導剤
RU2844734C1 (ru) Преимущественные терапии нарушений, опосредованных ikaros или aiolos
JP2025525917A (ja) Retタンパク質を調節するための化合物
US20250289827A1 (en) Morphic forms of a mutant braf degrader and methods of manufacture thereof
CN118660884A (zh) Cft7455的晶型物及其制造方法
WO2025129116A1 (en) Compounds for the targeted degradation of smarca2
JP2025540906A (ja) Ret-lddタンパク質阻害剤
WO2024173832A2 (en) Isoindolinone glutarimide and phenyl glutarimide analogs as degraders of ret kinase
BR112019027967A2 (pt) forma b cristalina isolada, composição farmacêutica, método para o tratamento de um distúrbio, método de um composto ou composição, e, processo para produzir forma b cristalina.